Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016

HAMPTON, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.

The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:

Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

Date/Time: Monday, April 18, 8:00 a.m. - 12:00 p.m. CDT
Location: Section 13
Abstract: CT023
Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma

Date/Time: Wednesday, April 20, 8:00 a.m. - 12:00 p.m. CDT
Location: Section 27
Abstract: 5032
Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues

Date/Time: Monday, April 18, 8:00 a.m. - 12:00 p.m. CDT
Location: Section 21
Abstract: 1373
Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy

Date/Time: Wednesday, April 20, 8:00 a.m. - 12:00 p.m. CDT
Location: Section 22
Abstract: 4866

The following investigator-sponsored abstracts have been selected for poster presentations at AACR:

Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy

Date/Time: Monday, April 18, 8:00 a.m. - 12:00 p.m. CDT
Location: Section 10
Abstract: LB-081

Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer

Date/Time: Tuesday, April 19, 1:00 p.m. - 5:00 p.m. CDT
Location: Section 33
Abstract: 4209
Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma

Date/Time: Sunday, April 17, 1:00 p.m. - 5:00 p.m. CDT
Location: Section 16
Abstract: 296

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.

Contact:

Sarah Cavanaugh

Vice President of Investor Relations & Corp Communications

Celldex Therapeutics, Inc.

(781) 433-3161

scavanaugh@celldex.com



Charles Liles

Manager of Investor Relations & Corp Communications

Celldex Therapeutics, Inc.

(781) 433-3107

cliles@celldex.com



Media Contact:



Dan BudwickPure Communications, Inc.

(973) 271-6085

dan@purecommunicationsinc.com

Source: Celldex Therapeutics, Inc.

News Provided by Acquire Media